权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nanoplasmonics-based molecular analysis tool for molecular biomarkers of cancer

基于纳米等离子体的癌症分子生物标志物分子分析工具

基本信息

批准号：
9321908
负责人：
Tuan Vo-Dinh
金额：
$ 23.7万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-08 至 2018-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9321908
关键词：
Adopted Area Barrett Esophagus Biological Assay Biological Markers Biological Models Biosensing Techniques Blood Blood specimen Clinic Clinical Competitive Binding Consumption DNA Detection Development Diagnosis Diagnostic Diagnostic tests Early Diagnosis Early Intervention Endoscopy Enrollment Esophageal Esophageal Adenocarcinoma Excision Future Goals Gold Human Incidence Investigation Label Malignant Neoplasms Malignant neoplasm of esophagus Malignant neoplasm of gastrointestinal tract Methods MicroRNAs Molecular Molecular Analysis Molecular Conformation Nanotechnology Northern Blotting Patients Polymerase Chain Reaction Process Research Resources Reverse Transcriptase Polymerase Chain Reaction Reverse Transcription Risk Risk Factors Sampling Scheme Screening for cancer Sentinel Shapes Signal Transduction Specificity Surface System Systems Analysis Techniques Technology Testing Time Tissues Translating accurate diagnosis anticancer research base cancer biomarkers cancer diagnosis cancer type clinical Diagnosis clinical diagnostics clinical practice clinical risk clinical translation cohort cost cost effective design diagnosis standard diagnostic accuracy diagnostic screening gastrointestinal improved innovation interest laboratory equipment microRNA biomarkers minimally invasive molecular marker multiplex detection nanoplasmonic nanoprobe new technology new therapeutic target novel novel diagnostics novel strategies peripheral blood plasmonics point of care public health relevance repository screening small molecule stem surveillance strategy tool

项目摘要

DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have demonstrated great promise as biomarkers for investigation of cancer development and progression and for early detection, yet these small molecules have not been adopted into early diagnostics for clinical practice because of challenging analytical aspects in the lab. Microarray-based technology, Northern blotting, sequencing, and qRT-PCR analyses are often employed, involving elaborate, time-consuming and expensive processes that require special laboratory equipment. There is a need to develop alternative molecular assay strategies that may offer more advantages over conventional methods and have the potential to enhance research in the areas of early detection and screening, and clinical diagnosis. Although miRNAs related to gastrointestinal (GI) cancer will be used as the model system, the proposed molecular analysis technology will be applicable generally to other types of cancers and other miRNA probes. We will develop a novel molecular analysis technology based on the "Inverse Molecular Sentinel" (iMS) scheme using surface-enhanced Raman scattering (SERS) detection that will move miRNA testing from an RT-PCR lab-based based assay scheme to a molecular analysis and testing technology that is simpler, faster and more cost effective. The specific aims of this project are: (1) Develop the new iMS molecular analysis method for multiplex detection of molecular biomarkers, miRNAs. Due to the highly specific and narrow SERS peaks, we will use the iMS technique to simultaneously detect multiple microRNA sequences as a simple and rapid multiplex screening tool for esophageal cancer. The analytical features of merit (specificity, sensitivity, probe stability) of the new molecular analysis technology will be investigated in detail. (2) Apply and evaluate the iMS molecular analysis method for diagnosis and investigation of GI cancer development and progression using clinical samples. We will demonstrate the usefulness of the iMS technique to detect miRNAs in peripheral blood samples from patients with known cancer diagnosis and from controls. In the clinical cohort, RT-PCR will be used as the gold standard for diagnosis, and nanoprobes will be tested against RT-PCR for diagnostic accuracy. The iMS biosensing system has the potential to be faster and more efficient than currently available systems, and is capable of providing great sensitivity with higher levels of specificity and multiplexing capabilities to screen microRNAs associated with Barrett's esophagus and esophageal cancer. In conclusion, the proposed molecular analysis technology represents a major innovation that has great transformative potential in cancer research, diagnostics and screening. The iMS approach is a `homogenous' assay (i.e., requiring no sample removal, and thus no microfluids). Also, the targets do not need to be labeled, thus reducing cost and complexity. The advantages of the novel molecular analysis technology would allow detection of multiple miRNA biotargets for research on cancer development and progression, and ultimately enable its future clinical translation to render a faster and more accurate diagnosis at point-of-care settings.